Bio-Techne rebrands genome engineering as part of R&D Systems portfolio

By The Science Advisory Board staff writers

September 21, 2020 -- Bio-Techne has rebranded its cell and gene engineering product offer as part of its R&D Systems biotechnology brand.

The company's B-MoGen Biotechnologies portfolio of genome engineering services, good manufacturing practice therapeutic manufacturing services, and proprietary transposon-transposase gene transfer system, TcBuster, has been rebranded under R&D Systems.

As part of the rebranding, the B-MoGen Biotechnologies website will be retired. All service details and purchasing options will be maintained on the R&D Systems website. The consolidation will help the company provide customers with discovery-to-clinic cell and gene therapy solutions.

Bio-Techne, Leica launch RNA probes for COVID-19 research
Bio-Techne and Leica Biosystems have announced the automation of RNAscope COVID-19 probes on Bond Rx, Leica's staining platform, for research use only....
Bio-Techne releases new SARS recombinant antibody
Bio-Techne has launched a SARS-CoV-1/2 spike receptor-binding domain LlamaBody recombinant antibody that blocks the virus from binding to the host receptor,...
Bio-Techne, Kantaro launch COVID-19 serology test
Bio-Techne and Kantaro Biosciences have launched COVID-SeroIndex, a quantitative SARS-CoV-2 immunoglobulin G antibody research-use only kit.
Bio-Techne releases product for manufacturing
Bio-Techne has released GMP ProDots Proteins to support cell and gene therapy manufacturing workflows. The product will allow manufacturers to safely...
Bio-Techne releases new T-cell activation kit
Bio-Techne has released a new kit for cell and gene therapy manufacturing called GMP Cloudz Human T Cell Activation.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter